The immunoassay instrument developer is targeting $57.5m in an offering that will provide exits for BioMerieux and Stratec Biomedical.
US-based biomarker detection instrument developer Quanterix has filed to raise up to $57.5m in an initial public offering that would allow diagnostics equipment makers BioMerieux and Stratec Biomedical to exit.
Quanterix has created an immunoassay platform that can find protein biomarkers in fluids such as blood or serum, even in low concentrations. It plans to put the IPO proceeds into growing its commercial activities, including the launch of its Quanterix SR-X instrument in 2018.
Additional cash will go to…
